The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

CVS struggled financially last year after underpricing some Aetna insurance plans and the government lowered quality ratings.

UnitedHealth Group is facing significant challenges to its finances, operations and reputation. Here's a look back at the ...

Playbook Conference – Strategies and Solutions for the Future of Healthcare is scheduled for April 2 in Nashville, Tennessee.

The industry could see payment, workforce and insurance coverage changes depending on how the Trump administration weighs in ...

Massive Medicaid cuts would damage access to post-acute care for older adults, LeadingAge President and CEO Katie Smith Sloan ...

A doctor, nurse and custodian were shot during the Saturday morning incident inside UPMC Memorial Hospital in West Manchester ...

The action, tied to two deaths, is among the latest in a surge of recalls by the agency, with nearly 100 Class I recalls in ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The hospital is expected to close in April. Orlando Health acquired the 298-bed facility from Steward Health Care last year.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...